About the Treatment

Mytocel MSK

Mytocel MSK uses Autologous Micrografting Technology (AMT®) to convert a small auricular cartilage sample into a tissue-specific suspension ready to inject.

Prepared during the same clinical session, Mytocel MSK delivers biologically active components directly to the target joint.

  • Autologous
  • Point-of-Care
  • Minimally Invasive
What does the Micrograft Suspension Contain?

The micrograft suspension contains all the components from the "diamond of regeneration" - Creating a unique regenerative micro-environment within the affected Osteoarthritis joint.

Chondroprogenitor Cells

Support cartilage repair signaling and promote new tissue formation pathways

Extracellular Matrix (ECM)

Support cartilage repair signaling and promote new tissue formation pathways

Anti-inflammatory Cytokines

Support cartilage repair signaling and promote new tissue formation pathways

Anabolic Growth Factors

Support cartilage repair signaling and promote new tissue formation pathways

Step-by-Step Protocol

The 5-Step Procedure

Completed within a single 30-minute clinical session — no surgery room required.

1

Double disinfection, anaesthesia and hydrodisection

Support cartilage repair signaling and promote new tissue formation pathways
2

Biopsy collection

Support cartilage repair signaling and promote new tissue formation pathways
3

Mechanical Dissagregation

Support cartilage repair signaling and promote new tissue formation pathways
4

Infiltration

The biologically active suspension is injected directly into the target joint.

See the Procedure in Action

Watch the Mytocel MSK procedure video

Key Advantages

Autologous & Tissue-Specific

Derived entirely from the patient's own cartilage — zero risk of rejection or immune response.

Minimally Invasive

Only a small biopsy taken from the ear. No surgical incision. No general anesthesia required.

No Downtime

Patients can resume normal daily activity shortly after the procedure with minimal restrictions.

Easy to Perform in 30 Minutes

The entire procedure fits comfortably within a standard clinical consultation session.

Single Session

One treatment is typically sufficient for mild to moderate OA — no multi-session protocols.

Clinical Indications

Mytocel MSK is designed for treating:

Clinically validated for a broad range of musculoskeletal conditions, with evidence supporting outcomes Osteoarthritis grades.

  • Grade I–III Advanced

    1 single stage MACI-like protocol"

  • Modified Surgical protocol

    Protocols

  • Cartilage Injuries

    * Selected cases

  • Tendinopathy

    Tendon conditions

  • Chondromalacia Patellae

    Patellar cartilage

  • Knee

  • Hip

  • Shoulder

  • Ankle

  • Thumb (Rizarthrosis)

3+ Years

Lasting clinical results

Clinical Comparison

Mytocel MSK vs Other Orthobiologics

A science-based comparison of the leading injectable Orth biologic options for osteoarthritis.

Characteristics Mytocel MSK AMT® MACI/ACI BMAC ATMSCs PRP & Blood derived products HA
Autologous Source Check Check Check Check Check Check
Viable cells Check Check Check Check Check Check
Tissue - specific Check Check Check Check Check Check
Typology Ambulatory Surgery room Ambulatory Ambulatory/surgery room Ambulatory Ambulatory
Time 30 min 2-4 hours 4-6 hours 2-4 hours 30 min 30 min
Posology 1 session 1 session 1 session 1 session 3-4 sessions Every 6 months
Indication OA, tendinopathy, cartilage damage Cartilage lesions bigger than 2 cm Intrarticular OA, OA, tendinopathy, muscular damage, bone remodelling Intrarticular OA, OA, tendinopathy, muscular damage, bone remodelling Intrarticular OA, OA, tendinopathy, cartilage damage OA, tendinopathy
Expert Opinions

What Experts Say About Us

Voices from leading orthopaedic surgeons and researchers who have worked with Mytocel MSK.

Portrait of Dr. Marco Marcarelli
Dr. Marco Marcarelli
Orthopaedic Surgeon

Degenerative joint disease is not only a cartilage problem — it is a disruption of the entire joint microenvironment. Autologous micrografting offers a biological approach to restoring that balance.

Portrait of Dr. Costas Tsoukas
Dr. Costas Tsoukas
Orthopaedic Surgeon

One of the most interesting aspects of autologous micrografting is the ability to obtain biologically active tissue directly at the point of care within the same clinical session.

Portrait of Dr. Anna Example
Dr. Anna Example
Orthopaedic Surgeon

Autologous micrografting can be prepared during the same clinical session to deliver biologically active components directly to the target joint, supporting regeneration and pain management.

Meet the Advisory Board
Events & Education

Upcoming Webinars & Events

Stay updated with upcoming webinars, congress participation and training sessions related to Mytocel MSK.

View All Events